Abstract
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by progressive joint destruction that requires aggressive treatment using appropriate disease-modifying antirheumatic drugs (DMARDs). RA patients with renal failure, however, are intolerant to most DMARDs due to the potential toxicity. In Japan, tacrolimus was approved for the treatment of RA in 2005. Based on its pharmacokinetics, tacrolimus may be administered to the patients undergoing hemodialysis. We report two cases of RA patients on hemodialysis treated effectively and safely with tacrolimus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Basile C, Basile C, Semeraro A. Should low-dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transplant. 2002;17:530–31.
Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother. 2002;36:75–7.
Iwamoto M, Homma S, Asano Y, Minota S. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol. 2005;34:410–1.
Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005;57:1407–13.
Tanaka Y, Suzuki K, Saito K. Efficacy of tacrolimus for joint destruction in rheumatoid arthritis. Clin Calcium. 2007;17:593–9.
Venkataramanan R, Jain A, Cadoff E, Warty V, Iwasaki K, Nagase K et al. Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc.1990;22:52–6.
Venkataramanan R, Jain A, Warty VW, Abu-Elmagd K, Furakawa H, Imventarza O et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc. 1991;23:931–3.
Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol. 1994;47:727–35.
Möller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633–6.
Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002;46:2020–8.
Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford). 2004;43:992–9.
Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis. 1998;57:110–3.
Wall SM, Johansen MJ, Molony DA, DuBose TD, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996;28:846–54.
Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol. 2002;29:636–7.
Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006;45:357–9.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yamashita, M., Natsumeda, M., Takasugi, K. et al. Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis. Mod Rheumatol 18, 296–300 (2008). https://doi.org/10.1007/s10165-008-0044-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-008-0044-1